Androgen stimulates endothelial cell proliferation via an androgen receptor/VEGF/cyclin A-mediated mechanism

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 300, Issue 4, 2011, Pages

  Cai, Jingjing ^a,b   Hong, Yuan ^b   Weng, Chunyan ^a,b   Tan, Chen ^a   Imperato McGinley, Julianne ^a   Zhu, Yuan Shan ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Dihydrotestosterone; Endothelium; Gene expression; Growth factor

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; BICALUTAMIDE; CYCLIN A; CYCLIN D1; DNA; ESTRADIOL; ROSCOVITINE; SEMAXANIB; SMALL INTERFERING RNA; TESTOSTERONE; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

AORTA; ARTICLE; CELL COUNT; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; CELL STIMULATION; CELL VIABILITY; CONTROLLED STUDY; DNA SYNTHESIS; DRUG INHIBITION; ENDOTHELIUM CELL; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HORMONAL REGULATION; HUMAN; HUMAN AORTIC ENDOTHELIAL CELL; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANDROGEN RECEPTOR ANTAGONISTS; ANILIDES; AORTA; CELL PROLIFERATION; CELLS, CULTURED; CYCLIN A; DIHYDROTESTOSTERONE; DNA; ENDOTHELIUM, VASCULAR; ESTRADIOL; GENE EXPRESSION; HUMANS; INDOLES; MALE; NITRILES; PROTEIN KINASE INHIBITORS; PURINES; PYRROLES; RECEPTORS, ANDROGEN; TESTOSTERONE; TOSYL COMPOUNDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79955066279     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01210.2010     Document Type: Article

References (60)

1. Balakumar P, Kaur T, Singh M. Potential target sites to modulate vascular endothelial dysfunction: current perspectives and future directions. Toxicology 245: 49-64, 2008.
2. Bernini G, Versari D, Moretti A, Virdis A, Ghiadoni L, Bardini M, Taurino C, Canale D, Taddei S, Salvetti A. Vascular reactivity in congenital hypogonadal men before and after testosterone replacement therapy. J Clin Endocrinol Metab 91: 1691-1697, 2006.
3. Buolamwini JK. Cell cycle molecular targets in novel anticancer drug discovery. Curr Pharm Des 6: 379-392, 2000.
4. Channer KS, Jones TH. Cardiovascular effects of testosterone: implications of the "male menopause"? Heart 89: 121-122, 2003.
5. Chung NA, Lydakis C, Belgore F, Li-Saw-Hee FL, Blann AD, Lip GY. Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease. Heart 89: 1411-1415, 2003.
6. Corvazier E, Dupuy E, Dosne AM, Maclouf J. Minimal effect of estrogens on endothelial cell growth and production of prostacyclin. Thromb Res 34: 303-310, 1984.
7. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation 102: 1906-1911, 2000.
8. Eriksson U, Alitalo K. Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Curr Top Microbiol Immunol 237: 41-57, 1999.
9. Felmeden DC, Spencer CG, Chung NA, Belgore FM, Blann AD, Beevers DG, Lip GY. Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT]). Am J Cardiol 92: 400-405, 2003.
10. Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol 106: 148-156, 2001.
11. Foresta C, Caretta N, Lana A, De Toni L, Biagioli A, Ferlin A, Garolla A. Reduced number of circulating endothelial progenitor cells in hypogo-nadal men. J Clin Endocrinol Metab 91: 4599-4602, 2006.
12. Gale NW, Thurston G, Davis S, Wiegand SJ, Holash J, Rudge JS, Yancopoulos GD. Complementary and coordinated roles of the VEGFs and angiopoietins during normal and pathologic vascular formation. Cold Spring Harb Symp Quant Biol 67: 267-273, 2002.
13. Gates PE, Strain WD, Shore AC. Human endothelial function and microvascular ageing. Exp Physiol 94: 311-316, 2009.
14. Gregory CW, Johnson RT Jr, Presnell SC, Mohler JL, French FS. Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft. J Androl 22: 537-548, 2001.
15. Gruenewald DA, Matsumoto AM. Testosterone supplementation therapy for older men: potential benefits and risks. J Am Geriatr Soc 51: 101-115, 2003.
16. Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, Trevisan M, Aragaki A, Baird AE, Bray PF, Buring JE, Criqui MH, Herrington D, Lynch JK, Rapp SR, Torner J. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 113: 2425-2434, 2006.
17. Hunter T, Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 79: 573-582, 1994.
18. Kang SM, Jang Y, Kim JY, Chung N, Cho SY, Chae JS, Lee JH. Effect of oral administration of testosterone on brachial arterial vasoreactivity in men with coronary artery disease. Am J Cardiol 89: 862-864, 2002.
19. Khaw KT, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, Welch A, Day N. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 116: 2694-2701, 2007.
20. Kintzel PE, Chase SL, Schultz LM, O'Rourke TJ. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmaco-therapy 28: 1511-1522, 2008.
21. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 93: 68-75, 2008.
22. Lee DK, Chang C. Endocrine mechanisms of disease: Expression and degradation of androgen receptor: mechanism and clinical implication. J Clin Endocrinol Metab 88: 4043-4054, 2003.
23. Levine AC, Liu XH, Greenberg PD, Eliashvili M, Schiff JD, Aaronson SA, Holland JF, Kirschenbaum A. Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology 139: 4672-4678, 1998.
24. Ling S, Komesaroff P, Sudhir K. Cellular mechanisms underlying the cardiovascular actions of oestrogens. Clin Sci (Lond) 111: 107-118, 2006.
25. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev 24: 313-340, 2003.
26. Ma R, Wu S, Lin Q. Homologous up-regulation of androgen receptor expression by androgen in vascular smooth muscle cells. Horm Res 63: 6-14, 2005.
27. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cy-tokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 89: 3313-3318, 2004.
28. Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH, Channer KS. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 90: 871-876, 2004.
29. Michels G, Hoppe UC. Rapid actions of androgens. Front Neuroendo-crinol 29: 182-198, 2008.
30. Michiels C. Endothelial cell functions. J Cell Physiol 196: 430-443, 2003.
31. Miller ME, Dores GM, Thorpe SL, Akerley WL. Paradoxical influence of estrogenic hormones on platelet-endothelial cell interactions. Thromb Res 74: 577-594, 1994.
32. Morales DE, McGowan KA, Grant DS, Maheshwari S, Bhartiya D, Cid MC, Kleinman HK, Schnaper HW. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation 91: 755-763, 1995.
33. Nettleship JE, Jones RD, Channer KS, Jones TH. Testosterone and coronary artery disease. Front Horm Res 37: 91-107, 2009.
34. Pestell RG, Albanese C, Reutens AT, Segall JE, Lee RJ, Arnold A. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr Rev 20: 501-534, 1999.
35. Qiao Y, Zhang ZK, Cai LQ, Tan C, Imperato-McGinley JL, Zhu YS. 17Alpha-estradiol inhibits LAPC-4 prostatic tumor cell proliferation in cell cultures and tumor growth in xenograft animals. Prostate 67: 1719-1728, 2007.
36. Rosano GM, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerqu-etani E, della Monica PL, Bonfigli B, Volpe M, Chierchia SL. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 99: 1666-1670, 1999.
37. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333, 2002.
38. Shepherd JT, Katusic ZS. Endothelium-derived vasoactive factors: I. Endothelium-dependent relaxation. Hypertension 18: III76-III85, 1991.
39. Sherr CJ. Cancer cell cycles. Science 274: 1672-1677, 1996.
40. Shibata Y, Kashiwagi B, Arai S, Fukabori Y, Suzuki K, Honma S, Yamanaka H. Direct regulation of prostate blood flow by vascular endothelial growth factor and its participation in the androgenic regulation of prostate blood flow in vivo. Endocrinology 145: 4507-4512, 2004.
41. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med 166: 1660-1665, 2006.
42. Sieveking DP, Lim P, Chow RW, Dunn LL, Bao S, McGrath KC, Heather AK, Handelsman DJ, Celermajer DS, Ng MK. A sex-specific role for androgens in angiogenesis. J Exp Med 207: 345-352, 2010.
43. Somjen D, Kohen F, Gayer B, Kulik T, Knoll E, Stern N. Role of putative membrane receptors in the effect of androgens on human vascular cell growth. J Endocrinol 180: 97-106, 2004.
44. Somjen D, Kohen F, Jaffe A, Amir-Zaltsman Y, Knoll E, Stern N. Effects of gonadal steroids and their antagonists on DNA synthesis in human vascular cells. Hypertension 32: 39-45, 1998.
45. Somjen D, Kohen F, Jaffe A, Amir-Zaltsman Y, Knoll E, Stern N. Effects of gonadal steroids and their antagonists on DNA synthesis in human vascular cells. Hypertension 32: 39-45, 1998.
46. Sordello S, Bertrand N, Plouet J. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochem Biophys Res Commun 251: 287-290, 1998.
47. Tan C, Cai LQ, Wu W, Qiao Y, Imperato-McGinley J, Chen GQ, Zhu YS. NSC606985, a novel camptothecin analog, induces apoptosis and growth arrest in prostate tumor cells. Cancer Chemother Pharmacol 63: 303-312, 2009.
48. The Coronary Drug Project. Findings leading to discontinuation of the 25-mg day estrogen group The coronary Drug Project Research Group. JAMA 226: 652-657, 1973.
49. The Veterans Administration Co-operative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124: 1011-1017, 1967.
50. Tivesten A, Hulthe J, Wallenfeldt K, Wikstrand J, Ohlsson C, Fager-berg B. Circulating estradiol is an independent predictor of progression of carotid artery intima-media thickness in middle-aged men. J Clin Endo-crinol Metab 91: 4433-4437, 2006.
51. Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation 108: 2054-2059, 2003.
52. Wegiel B, Bjartell A, Tuomela J, Dizeyi N, Tinzl M, Helczynski L, Nilsson E, Otterbein LE, Harkonen P, Persson JL. Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis. J Natl Cancer Inst 100: 1022-1036, 2008.
53. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Bohm M, Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353: 999-1007, 2005.
54. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rosel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60: 2178-2189, 2000.
55. Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 24: 183-217, 2003.
56. Yasui M, Yamamoto H, Ngan CY, Damdinsuren B, Sugita Y, Fuku-naga H, Gu J, Maeda M, Takemasa I, Ikeda M, Fujio Y, Sekimoto M, Matsuura N, Weinstein IB, Monden M. Antisense to cyclin D1 inhibits vascular endothelial growth factor-stimulated growth of vascular endothe-lial cells: implication of tumor vascularization. Clin Cancer Res 12: 4720-4729, 2006.
57. Zhu YS. Molecular basis of steroid action in the prostate. Cellsci Rev 1: 27-55, 2005.
58. Zhu YS, Katz MD, Imperato-McGinley J. Natural potent androgens: lessons from human genetic models. Baillieres Clin Endocrinol Metab 12: 83-113, 1998.
59. Zhu YS, Pfaff DW. Differential regulation of AP-1 DNA binding activity in rat hypothalamus and pituitary by estrogen. Mol Brain Res 55: 115-125, 1998.
60. Zou JX, Zhong Z, Shi XB, Tepper CG, deVere White RW, Kung HJ, Chen H. ACTR/AIB1/SRC-3 and androgen receptor control prostate cancer cell proliferation and tumor growth through direct control of cell cycle genes. Prostate 66: 1474-1486, 2006.